Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study.

Literature DB >> 15022346

Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study.

Yair Levy¹, Howard Amital, Pnina Langevitz, Francesca Nacci, Anna Righi, Letizia Conforti, Sergio Generini, Marco Matucci Cerinic, Yehuda Shoenfeld.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2004 PMID： 15022346 DOI： 10.1002/art.20195

Source DB: PubMed Journal: Arthritis Rheum ISSN： 0004-3591

Keyword Cloud
Cited

× No keyword cloud information.

28 in total

Review 1. Intravenous immunoglobulin and fibrosis.

Authors: Vered Molina; Miri Blank; Yehuda Shoenfeld
Journal: Clin Rev Allergy Immunol Date: 2005-12 Impact factor: 8.667

Review 2. Immunotherapy of systemic sclerosis.

Authors: Rebecca Manno; Francesco Boin
Journal: Immunotherapy Date: 2010-11 Impact factor: 4.196

3. Prevention of excessive collagen accumulation by human intravenous immunoglobulin treatment in a murine model of bleomycin-induced scleroderma.

Authors: M Kajii; C Suzuki; J Kashihara; F Kobayashi; Y Kubo; H Miyamoto; T Yuuki; T Yamamoto; T Nakae
Journal: Clin Exp Immunol Date: 2010-11-22 Impact factor: 4.330

4. Combined plasmapheresis and high-dose intravenous immunoglobulin treatment in systemic sclerosis for 12 months: follow-up of immunopathological and clinical effects.

Authors: Zoltán Szekanecz; Magdolna Aleksza; Péter Antal-Szalmás; Pál Soltész; Katalin Veres; Sándor Szántó; Zoltán Szabó; Anikó Végvári; Szilvia Szamosi; Gabriella Lakos; Sándor Sipka; Gyula Szegedi; John Varga; Gabriella Szücs
Journal: Clin Rheumatol Date: 2008-12-06 Impact factor: 2.980

Review 5. Recent advances in the treatment of systemic sclerosis.

Authors: Vasiliki Kalliopi K Bournia; Panayiotis G Vlachoyiannopoulos; Carlo Selmi; Haralampos M Moutsopoulos; M Eric Gershwin
Journal: Clin Rev Allergy Immunol Date: 2009-06 Impact factor: 8.667

6. Intravenous immunoglobulins for rheumatic disorders and thromboembolic events-a case series and review of the literature.

Authors: Merav Lidar; Sewar Masarwa; Pnina Rotman; Or Carmi; Noa Rabinowicz; Yair Levy
Journal: Immunol Res Date: 2018-12 Impact factor: 2.829

Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study.

Review 1. Intravenous immunoglobulin and fibrosis.

Review 2. Immunotherapy of systemic sclerosis.

3. Prevention of excessive collagen accumulation by human intravenous immunoglobulin treatment in a murine model of bleomycin-induced scleroderma.

4. Combined plasmapheresis and high-dose intravenous immunoglobulin treatment in systemic sclerosis for 12 months: follow-up of immunopathological and clinical effects.

Review 5. Recent advances in the treatment of systemic sclerosis.

6. Intravenous immunoglobulins for rheumatic disorders and thromboembolic events-a case series and review of the literature.

7. Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis.

Review 8. Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future.

9. An Update on the Treatment of the Cutaneous Manifestations of Systemic Sclerosis: The Dermatologist's Point of View.

Review 10. My approach to the treatment of scleroderma.